A new report by Reports and Data has revealed that the global Spine Biologics Market is expected to reach USD 2,629.6 Million by 2027. The growth of the spine biologics market is being influenced by the increasing occurrence of spine disorders worldwide.

According to the World Health Organization (WHO), each year, 250,000 to 500,000 people suffer from a spinal cord injury globally, with preventable causes such as road traffic accidents, falls, or violence being the major contributors. Individuals suffering from spinal cord injuries have a higher risk of premature death compared to healthy individuals, with low and middle-income economies having the worst survival rates.

Get a free sample PDF of the report, visit @

https://www.reportsanddata.com/download-free-sample/3495

Spinal cord injury is associated with a high risk of secondary conditions such as urinary tract infections, deep vein thrombosis, muscle spasms, pressure ulcers, osteoporosis, chronic pain, and respiratory complications.

The report also highlighted the impact of aging on the spine biologics market, with the number of people aged 65 years or older expected to increase from a projected 524 million in 2010 to approximately 1.5 billion by 2050, with a significant percentage of increase in developing economies. Aging leads to the deterioration of facet joints resulting in several spinal disorders. Therefore, the increasing prevalence of diseases in the growing geriatric population is likely to propel the growth of the spine biologics market in the forecast period.

The COVID-19 pandemic has had a significant impact on the spine biologics industry. Demand for spine biologics materials has seen a decrease in demand, owing to mandatory lockdowns resulting in movement restrictions to curb the spread of the infectious virus, especially in older adults, who are at a higher risk of contracting the disease attributed to the weaker immune system. Lockdown restriction is causative of the disruption of the value chain, which, in turn, has an impact on the supply of biologics material required for the treatment of spinal deformities.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/3495

By type, bone graft substitutes are estimated to grow at a rate of 4.3% in the forecast period. By surgery type, the transforaminal lumbar interbody fusion (TLIF) held a substantial spine biologics market size in 2019. By end-user, ambulatory surgical centers held the second-largest spine biologics market share in 2019 and are likely to witness the fastest growth rate of 4.7% in the forecast period.

The Asia Pacific region is likely to grow at the fastest rate of 5.0% in the period 2019-2027, due to the improving healthcare infrastructure, rising investments in biologics development, and better reimbursement scenario. Key participants in the spine biologics market include Medtronic PLC, Stryker Corporation, Nuvasive Inc., Zimmer Holding Inc., K2M Inc., Exactech Inc., Nutech Inc., Depuy Synthes, Wright Medical Technology, and Orthofic International NV, among others.

In May 2019, Medtronic PLC, a leading market player, signed an agreement for the acquisition of Titan Spine, a private company, dealing in titanium spine surface and interbody implant technology. The acquisition is expected to accelerate Medtronic's plans to innovate spinal treatment methods and advance outcomes.

The global spine biologics market has been segmented by Reports and Data on the basis of type, surgery type, end-user, and region. The report provides revenue estimates in USD million from 2017 to 2027 for each segment. The types of spine biologics include spinal allografts, bone graft substitutes, cell-based matrix, and others. Surgery types include anterior cervical discectomy and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF).

Request a customized copy of the report @

https://www.reportsanddata.com/request-customization-form/3495

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs